Search

EVA is an important if uncommon disease of horses. Potential economic losses attributable to EVA include direct losses from abortion, pneumonia in neonates, and febrile disease in performance horses. Indirect losses are those associated with national and international trade/animal movement regulations, particularly those pertaining to persistently infected carrier stallions and their semen. However, EAV infection and EVA are readily prevented through serological and virological screening of horses, coupled with sound management practices that include appropriate quarantine and strategic vaccination.

A serological study for antibodies against equine arteritis virus (EAV) in Finland was performed during 1996. All equine sera delivered to the Virology Unit at the National Veterinary and Food Research Institute were tested with a micro-neutralization test, using the Arvac strain as antigen. The study also included imported horses to evaluate EAV circulation in the countries of origin. Nucleocapsid gene sequences of 2 Finnish equine semen isolates were amplified with RT-PCR and sequenced. The genetic relationships of those isolates with strains isolated elsewhere in the world were analyzed. The Finnish isolates shared 98.2% nucleotide identity, and the closest relatives to the Finnish strains were isolated from the semen of 2 Norwegian horses in 1988 and 1989.